A Case Series of Drotrecogin Alfa (Activated) in Lung Transplant Recipients
Authors:
- Titus L. DanielsTDTitus L. Daniels
- J Stephen DummerJDJ Stephen Dummer
- Gordon R. BernardGBGordon R. Bernard
- Aaron P. MilstoneAMAaron P. Milstone
- 27 June 2006
- journal article
- case report
- Published by Wolters Kluwer Health in Transplantation
- Vol. 81 (12) , 1739-1742
Abstract
Severe sepsis in lung transplant recipients is a challenging problem and carries a high mortality. Recombinant human activated protein C (drotrecogin alfa [activated]) has been approved for use in patients with severe sepsis. Its use has been shown to be safe and impart a survival advantage. However, the safety of drotrecogin alfa activated has not been evaluated in lung transplant recipients. We report for the first time on the use of drotrecogin alfa activated in six lung transplant recipients. Clinical trials are warranted to further evaluate the use of drotrecogin alfa activated in transplant recipients.Keywords
This publication has 12 references indexed in Scilit:
- A Blueprint for a Sepsis ProtocolAcademic Emergency Medicine, 2005
- Therapeutic Intervention and Targets for SepsisAnnual Review of Medicine, 2005
- Extended Evaluation of Recombinant Human Activated Protein C United States Trial (ENHANCE US)Chest, 2004
- Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsisTransplantation, 2003
- Coagulation inhibition for sepsisCurrent Opinion in Hematology, 2002
- Septic shock and multiple organ failure after hematopoietic stem cell transplantation: treatment with recombinant human activated protein CBone Marrow Transplantation, 2002
- Infectious complications of lung transplantationTransplant Infectious Disease, 2001
- Low Levels of Protein C Are Associated With Poor Outcome in Severe SepsisChest, 2001
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisChest, 1992